Neogenix Oncology, Inc. (Neogenix) announced today that the company has been awarded two grants totaling $488,958.50, under the Qualifying Therapeutic Discovery Project Program. The two successful applications were for the company's h16C3 therapeutic antibody development program and the diagnostic biomarker development program for both their h16C3 and NPC-1C antibodies.
Invented and developed by Neogenix Oncology, the h16C3 monoclonal antibody has shown anti-tumor effects for both pancreatic and colorectal tumors in both in vitro and animal studies. The h16C3 antibody is in clinical development for a diagnostic product and in pre-clinical development for therapeutic utility. The company's NPC-1C monoclonal antibody, in addition to being evaluated with h16C3 as part of a clinical diagnostic program, is currently in a Phase I multi-center clinical trial at Johns Hopkins Hospital, Duke University Medical Center and North Shore LIJ for advanced colorectal and pancreatic cancer.
"We are very pleased to be receiving these federal grants for the development of our h16C3 and NPC-1C antibody diagnostic program as well as our h16C3 therapeutic program. We are excited about moving these product candidates forward, while continuing the clinical trial of our NPC-1C monoclonal antibody for colorectal and pancreatic cancer."
Expanding research and clinical options for children with cancer